BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1277 related articles for article (PubMed ID: 15459300)

  • 1. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
    J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
    de Pauw BE; Sable CA; Walsh TJ; Lupinacci RJ; Bourque MR; Wise BA; Nguyen BY; DiNubile MJ; Teppler H
    Transpl Infect Dis; 2006 Mar; 8(1):31-7. PubMed ID: 16623818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
    Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
    Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.
    Maertens JA; Madero L; Reilly AF; Lehrnbecher T; Groll AH; Jafri HS; Green M; Nania JJ; Bourque MR; Wise BA; Strohmaier KM; Taylor AF; Kartsonis NA; Chow JW; Arndt CA; DePauw BE; Walsh TJ;
    Pediatr Infect Dis J; 2010 May; 29(5):415-20. PubMed ID: 20431381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy.
    Stam WB; Aversa F; Kumar RN; Jansen JP
    Value Health; 2008; 11(5):830-41. PubMed ID: 18494752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
    Keating G; Figgitt D
    Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Schneemann M; Imhof A
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
    [No Abstract]   [Full Text] [Related]  

  • 15. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
    Klastersky J
    N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
    [No Abstract]   [Full Text] [Related]  

  • 16. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 17. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Marty FM; Lowry CM
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
    [No Abstract]   [Full Text] [Related]  

  • 18. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Jones BL; McLintock LA
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
    Wingard JR; Leather HL; Wood CA; Gerth WC; Lupinacci RJ; Berger ML; Mansley EC
    Am J Health Syst Pharm; 2007 Mar; 64(6):637-43. PubMed ID: 17353573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.